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Abstract
The stress hormone cortisol modulates fuel metabolism, cardiovascular homoeostasis, mood, inflammation and cognition.
The CORtisol NETwork (CORNET) consortium previously identified a single locus associated with morning plasma
cortisol. Identifying additional genetic variants that explain more of the variance in cortisol could provide new insights into
cortisol biology and provide statistical power to test the causative role of cortisol in common diseases. The CORNET
consortium extended its genome-wide association meta-analysis for morning plasma cortisol from 12,597 to 25,314 subjects
and from ~2.2 M to ~7M SNPs, in 17 population-based cohorts of European ancestries. We confirmed the genetic
association with SERPINA6/SERPINA1. This locus contains genes encoding corticosteroid binding globulin (CBG) and α1-
antitrypsin. Expression quantitative trait loci (eQTL) analyses undertaken in the STARNET cohort of 600 individuals
showed that specific genetic variants within the SERPINA6/SERPINA1 locus influence expression of SERPINA6 rather than
SERPINA1 in the liver. Moreover, trans-eQTL analysis demonstrated effects on adipose tissue gene expression, suggesting
that variations in CBG levels have an effect on delivery of cortisol to peripheral tissues. Two-sample Mendelian
randomisation analyses provided evidence that each genetically-determined standard deviation (SD) increase in morning
plasma cortisol was associated with increased odds of chronic ischaemic heart disease (0.32, 95% CI 0.06–0.59) and
myocardial infarction (0.21, 95% CI 0.00–0.43) in UK Biobank and similarly in CARDIoGRAMplusC4D. These findings
reveal a causative pathway for CBG in determining cortisol action in peripheral tissues and thereby contributing to the
aetiology of cardiovascular disease.
Introduction
Cortisol plays a vital role in adaptation to environmental stress,
modulating fuel metabolism, cardiovascular homoeostasis,
mood, memory and inflammation [1]. Cortisol levels vary
throughout the day under the control of the
hypothalamic–pituitary–adrenal (HPA) axis. Patients with
tumours causing excess cortisol develop Cushing’s syndrome,
characterised by a host of features including obesity, hyper-
tension, diabetes mellitus, depression, cognitive impairment
and osteoporosis with an excess mortality due primarily to
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cardiovascular disease [2]. Similarly, higher plasma cortisol in
the population associates with hypertension, hyperglycaemia,
cardiovascular disease, type 2 diabetes, cognitive dysfunction
and depression, while lower cortisol associates with immuno-
logical abnormalities and post-traumatic stress disorder [3–10].
We established the CORtisol NETwork (CORNET) con-
sortium with the initial aim of identifying genetic determinants
of inter-individual variation in HPA axis function. A genome-
wide association meta-analysis (GWAMA), investigating
~2.2M SNPs in 12,597 individuals from 11 European cohorts,
identified a single locus on chromosome 14 associated with
morning plasma cortisol at genome-wide significance [11]. The
locus spans SERPINA6 and SERPINA1 and influences function
of corticosteroid-binding globulin (CBG, the product of SER-
PINA6), a protein that binds cortisol in the blood. However, it
was unclear if the effect is mediated directly through SER-
PINA6 or indirectly through the product of SERPINA1, α1-
antitrypsin, which is involved in regulating cleavage and
inactivation of CBG [12]. Using these genetic variants as a
proxy for morning plasma cortisol levels in Mendelian rando-
misation analyses we provided evidence to suggest that cortisol
is a causal risk factor for coronary heart disease, but the odds
ratio was not statistically significant (OR: 1.06, 95% CI:
0.98–1.15) [13]. An independent study has confirmed recently
that common variants in SERPINA6 are associated with plasma
cortisol and with coronary artery disease [14].
The genetic variants in the SERPINA6/A1 locus explain
only ~0.5% of the variance in morning plasma cortisol.
Moreover, attempts to identify genetic variants associated with
an alternative phenotype of salivary cortisol have not been
successful [15]. Identifying additional genetic variants that
explain more of the variance in cortisol could provide new
insights into cortisol biology and statistical power to test the
causative role of cortisol in the aetiology of other common
diseases. We aimed: to identify additional specific loci influ-
encing cortisol; to refine where in the SERPINA6/A1 locus
there is an influence on cortisol; to establish whether SER-
PINA6/A1 variation influences tissue-specific expression of
CBG and α1-antitrypsin; and to confirm whether high cortisol
is causal in ischaemic heart disease and test if it is causal in
other common diseases. To achieve these aims, we undertook
an extended GWAMA analysis, with more subjects and more
SNPs than the original CORNET GWAMA [11], and used the
results to provide instruments for expression quantitative trait
loci (eQTL) and Mendelian randomisation analyses.
Methods
Genome-wide association meta-analysis study
We performed a meta-analysis of genome-wide association
studies of morning plasma cortisol in 25,314 subjects from 17
European population-based cohorts: CROATIA-Vis (n = 886),
CROATIA-Korcula (n = 897), CROATIA-Split (n = 493),
ORCADES (n = 1974), Rotterdam Study (n = 2870),
NFBC1966 (n = 1324), Helsinki Birth Cohort Study 1934–44
(n = 399), ALSPAC (n = 1487), PREVEND (n = 1151),
PIVUS (n = 919), Raine Study (n= 860), ET2DS (n = 847),
MrOS-Sweden (n = 969), KORA (n= 1651), TwinsUK (n=
5654), SHIP (n = 910) and VIKING (n= 2073). Character-
istics of the study populations are presented in Table S1 and
details of each cohort are provided in Supplementary Material.
All individuals were of European ancestries. Exclusion criteria
were current glucocorticoid use, pregnant or breast-feeding
women, and twins (exclusion of one of each twin pair). Cor-
tisol was measured by immunoassay in blood samples col-
lected from study participants between 0700 and 1100 h in all
cohorts except for in TwinsUK which measured cortisol using
liquid chromatography-mass spectrometry. All participants
provided written informed consent and studies were approved
by local Research Ethics Committees and/or Institutional
Review Boards.
Each study performed linear regression on z-scores of log-
transformed morning plasma cortisol (additive genetic effects),
adjusted for sex, age and cohort-specific genetic ancestry.
Additional models also adjusted for smoking and body mass
index. Imputation of the gene-chip results used the 1000
Genomes European population reference panel. Details of the
genotyping, imputation and cohort-specific adjustment for
genetic ancestry are provided in Table S2 and Supplementary
Material.
Quality control was carried out on the imputed genome-
wide data for all 17 studies prior to meta-analysis; this excluded
all SNPs with a minor allele frequency (MAF) <0.5%, call rate
<95%, and poor imputation quality (MACH R2_HAT <0.30,
IMPUTE PROPER_INFO <0.60, BEAGLE INFO <0.30, as
appropriate). Furthermore, only SNPs with estimates from at
least four studies were included, resulting in a final number of
8,452,427 SNPs. Quantile–quantile (QQ) plots and genomic
control (lambda) were used to assess evidence for population
structure that was not accounted for in association analyses.
Sex chromosomes were not analysed. Quality control at the
study-level and meta-level was performed using EasyQC
software [16].
The results from all cohorts were combined into a fixed-
effects meta-analysis using Stouffer’s method with
weighting of Z-scores proportional to the square-root of the
number of individuals in each sample, using METAL
software [17]. Manhattan and QQ plots visualised the
results using EasyStrata software [18].
SNP-based heritability
Linkage disequilibrium (LD) score regression exploits the
relationship between SNP-phenotype association strengths
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and LD patterns [19]. Assuming true causal effects, the
SNPs which are in higher LD with nearby SNPs are
expected to have more inflated test statistics, because they
are more likely to tag causal variants with stronger effects.
The SNP heritability was estimated using LD score
regression v1.9.0 [19]. Since imputation quality can con-
found LD score regression results, we restricted the analysis
to a list of well-imputed SNPs, as recommended by the
software authors. After applying default quality control
settings, the final SNP number was 1,028,327. The genome-
wide summary statistics were partitioned into functional
categories using the method described by Finucane et al.
[20]. More details of the partitioned heritability method can
be found in the Supplementary Material.
Genetic correlations
Genetic correlations between morning plasma cortisol and
selected diseases and traits from UK Biobank were esti-
mated using bivariate LD score regression. This technique
examines the correlation structure of genetic effects of SNPs
across the genome. The data processing pipeline devised by
Bulik-Sullivan et al. [21] was followed using LD Hub
v1.9.0 software [22].
Gene- and pathway-based association analysis
Gene- and pathway- based associations, which assign SNPs to
genes and biological pathways respectively, were performed
using MAGMA and FUMA software [23, 24]. SNPs were
assigned to 18,062 genes using the National Centre for Bio-
technology Information build 37.3. The gene boundary was
defined as the start and stop site of each gene. The European
panel of the 1000 Genomes data (phase 1, release 3) was used
as a reference panel to account for LD between the SNPs. A
Bonferroni correction was used to control for 18,062 tests
(α= 0.05/18 062; P < 2.768 × 10−6).
eQTL analysis in the Stockholm Tartu
Atherosclerosis Reverse Networks Engineering Task
(STARNET) study
eQTL analyses were undertaken in the STARNET study which
is composed of Caucasian individuals of Eastern European
origin (30% female), with a confirmed diagnosis of coronary
artery disease. Of these individuals 27% had diabetes, 77% had
hypertension and 37% had suffered a myocardial infarction
before the age of 60 years. Genotyping and RNA sequencing
of seven vascular and metabolic tissue samples from 600
patients undergoing coronary artery bypass surgery was per-
formed [25]. The tissue sets available in STARNET include;
whole blood, atherosclerotic-lesion free internal mammary
artery, atherosclerotic aortic root, subcutaneous fat, visceral
abdominal fat, skeletal muscle, and liver. Whole blood samples
were taken pre-operatively and the remaining tissue biopsies
were obtained during surgery.
For the analysis, we included 580 SNPs within SER-
PINA6/SERPINA1 locus on chromosome 14 identified from
the CORNET plasma cortisol GWAMA, defined as within
100 Kb of SERPINA6 (±of the transcription start/end point),
with no missing data, and MAF >5%. All transcripts were
annotated using the Human Genome Reference Consortium
Human Build 37 (GRCh37).
Transcriptome-wide eQTL associations between selected
SNPs and all genes expressed in the STARNET tissues
were tested using the Kruskal–Wallis test, a non-parametric
ANOVA used to determine whether sample groups origi-
nate from the same distribution that has been used pre-
viously in genetic association studies [26]. Kruskal–Wallis
test statistics and p values were computed using the kruX
algorithm [27], using available pre-processed and normal-
ised genotype and expression data matrices [25] as input.
Multiple testing correction was performed for all SNP
associations with every STARNET gene in each tissue
separately by calculating q values [28] using the qvalue
package in Python. eQTL associations with SERPINA6
were visualised using the GWAS visualisation tool Locus-
Zoom [29]. The allelic effect of individual SNPs on SER-
PINA6 was visualised by constructing boxplots for each
allele.
The global tissue-specific effect on gene expression for
SNPs associated with plasma cortisol at a genome-wide level
of significance was depicted using Q–Q plots showing the
observed transcriptome-wide SNP-gene associations against
the expected uniform distribution. Deviation from the uniform
distribution was tested using the Kolmogorov–Smirnov test
statistic and p value for each SNP.
Bayes factor colocalisation analysis was performed in R
using the package Coloc [30]. eQTL analysis was repeated
using linear regression with the R package MatrixEQTL
[31] to obtain beta values required for colocalisation. linear
regression and Kruskal–Wallis p values were consistent
(Fig. S7). For visualisation of the colocalisation event, LD
with the lead SNP was calculated using the package
LDlinkR [32].
Two-sample Mendelian randomisation
The instrument for morning plasma cortisol consisted of
independent (r2 < 0.3) genetic variants that reached a
genome-wide level of significance (P < 5 × 10−8). To detect
independent top SNPs we used the clumping function as
implemented in PLINK. The European samples from the
1000 Genomes Project were used to estimate LD between
SNPs. Amongst those SNPs within 1000 kb and r2 < 0.3,
only the SNP with the lowest P value was retained.
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Two-sample Mendelian randomisation [33] was used to
estimate the causal effect of morning plasma cortisol on
hypothetically cortisol-related diseases and traits (chronic
ischaemic heart disease, myocardial infarction, diabetes
mellitus, body mass index and osteoporosis) available in
UK Biobank and publicly available GWAS consortia in the
MR Base platform [34].
Genetic instruments for various traits/conditions were
also constructed to estimate the causal effect these had on
morning plasma cortisol (bidirectional Mendelian rando-
misation). Details of the selected disease and traits, the
population, consortia details and genetic instruments are
provided in Table S3. The SNP-cortisol estimate was divi-
ded by the SNP-outcome estimate (Wald ratio method [35])
and then combined using inverse variance weighting.
Additional analyses described in the Supplementary Mate-
rial were performed to investigate the robustness of this
causal estimate and any potential pleiotropic effects.
Results
Genome-wide association meta-analysis
The GWAMA of morning plasma cortisol levels in 25,314
identified a single locus on chromosome 14 reaching a
genome-wide level of significance (p < 5 × 10−8) (Fig. 1).
This is the same locus as the CORNET consortium pre-
viously identified [11] and includes the SERPINA6 gene,
encoding corticosteroid binding globulin (CBG), and the
SERPINA1 gene, encoding α1-antitrypsin, an inhibitor of
neutrophil elastase which cleaves and inactivates CBG. In
an additive genetic model, the top SNP rs9989237 reported
a per minor allele effect of 0.11 cortisol z-score (p = 2.2 ×
10−19). The effect allele frequency was 0.22 and this var-
iation explained 0.13% of the morning plasma cortisol
variance. Within this locus we identified four blocks of
SNPs in low LD (r2 < 0.3) visualised in Figs. 1, S1.
Fig. 1 a Manhattan plot of −log10 P values of the SNP-based asso-
ciation analysis of morning plasma cortisol (n= 25,314). The locus
on chr14 spans SERPINA6 and SERPINA1 genes; no other loci
reached genome-wide significance. b, c Zoomed in Manhattan plot
(LocusZoom plot) of −log10 P values of the SNP-based association
analysis of morning plasma cortisol (n= 25,314). These show two (of
the four) LD blocks (r2 > 0.3) in this locus
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SNP-based heritability
Using LD score regression, common SNPs across the
genome were found to explain 4.2% (s.e. 1.9%) of the
phenotypic variation of morning plasma cortisol. There was
no evidence of enrichment in a particular cell type, and
particularly not in the adrenal/pancreas or liver cell type
groups of SNPs, when partitioning the heritability into
functional cell types (all P values > 0.5, Table S4).
Genetic correlations
LD score regression was used to test whether genetic var-
iants associated with morning plasma cortisol also con-
tribute to health-related traits. Estimated genetic correlations
are presented in Fig. S2. There was evidence of a positive
genetic correlation between morning plasma cortisol and
acute myocardial infarction (rg= 0.50, 95% CI 0.04–0.97)
and a negative genetic correlation with BMI (rg=−0.32,
95% CI −0.54 to −0.10).
Gene-based and pathway-based association
analyses
Gene-based association analysis identified three genes, SER-
PINA6, SERPINA1 and SERPINA10, all located on chromo-
some 14, that attained genome-wide significance following
correction for multiple comparisons (Fig. S3). Pathway-based
association analysis identified the top pathway as metabolism
of lipids and lipoproteins (P= 1.6 × 10−5) (Table S5).
Tissue-specific eQTL analyses
The statistical effects of 580 SNPs in the SERPINA6 region
on gene expression were obtained using individual-level
genotype and RNA-sequencing data from seven vascular
and metabolic tissues from the STARNET study [25].
Following multiple testing correction (q ≤ 0.05), 32 cis-
eQTLs for SERPINA6 were identified in the liver, the only
tissue where SERPINA6 is highly expressed (Fig. 2a). Of
these 32 cis-eQTLs, 21 were also at genome-wide
Fig. 2 Tissue-specific association of cortisol-related SNPs with gene
expression in STARNET. a LocusZoom plot showing genomic loci of
given SNPs against measure of significance (−log10 (p value)) for an
eQTL analysis in liver for all SNPs within 100 Kb of SERPINA6.
Squares represent the 21 significant cis-eQTLs (q ≤ 0.05) that are also
at genome-wide significance in CORNET (p ≤ 5 × 10−8). b Genotypic
effect of representative SNP for LD block 2 (rs2736898) on
SERPINA6 gene expression in liver. c Global tissue-specific effects on
gene expression for rs2736898 represented as Q–Q plots for genes in
liver, subcutaneous fat and visceral abdominal fat describing observed
p values vs. those expected by chance. Deviation from expected uni-
form distribution described by Kolmogorov–Smirnov test p value (Ks-
test)
Variation in the SERPINA6/SERPINA1 locus alters morning plasma cortisol, hepatic corticosteroid. . .
significance in CORNET (p ≤ 5 × 10−8), and therefore also
associated with variation for plasma cortisol (Table S6).
The global effect on tissue-specific gene expression of
representative SNPs from each LD block was assessed
using the distribution of transcriptome-wide eQTL p values
(Figs. S4, S5). LD block 2, represented by the SNP
rs2736898, with the alternate allele C, exerted a negative
effect on SERPINA6 expression in liver (q= 0.00015)
(Fig. 2b) and showed the strongest tissue-specific effects,
particularly in visceral abdominal fat, subcutaneous fat and
liver (Fig. 2c). In all cases the allele associated with higher
plasma cortisol in the GWAMA was the allele associated
with higher SERPINA6 expression in STARNET (Fig. S6).
To determine if the signal identified for SERPINA6 cis-
eQTLs in liver and SNPs associated with plasma cortisol are
driven by the same causal variant, Bayes factor colocali-
sation analysis was performed while accounting for allelic
heterogeneity [30] (Fig. 3). The probability of both traits
sharing a causal variant was low (40.6%) when examining
all SNPs within 100 Kb of SERPINA6. However, when
examining each LD block individually, the block repre-
sented by rs2736898 returns a 99.2% probability of shared
causal variant in this region (Table S7).
Two-sample Mendelian randomisation
The clumping procedure identified four SNPs (rs9989237,
rs2736898, rs11620763, rs7146221) as markers represent-
ing genome-wide significant signals in this region. Two-
sample Mendelian randomisation analyses provided evi-
dence that each genetically-determined standard deviation
(SD) increase in morning plasma cortisol was associated
with an increased risk of chronic ischaemic heart disease
(0.32, 95% CI 0.06–0.59) and myocardial infarction (0.21,
95% CI 0.00–0.43) in UK Biobank (Fig. 4a). Similar esti-
mates were observed for these disease outcomes in non-UK
Biobank cohorts (CARDIoGRAM plus C4D, Fig. 4b).
The bidirectional Mendelian Randomisation analyses,
estimating the genetically predicted effect of various traits
or disease on plasma cortisol, did not support any causal
associations (Fig. 5).
Discussion
These results confirm that genetic variation in the SER-
PINA6/A1 locus on chromosome 14 is associated with
morning plasma cortisol. Despite doubling the sample size
and trebling the SNP density from the previous genome-
wide association study [11] no new genetic loci were
identified. The improved imputation of genetic markers
used in this analysis allowed identification of new SNPs
within the SERPINA6/A1 locus and strengthened the
instrument used in two-sample Mendelian randomisation
analyses. This additional information coupled with tissue-
specific gene expression data suggests that genetic variation
within this locus influences expression of SERPINA6 rather
than SERPINA1 in the liver. Furthermore, it appears that the
eQTL and GWAMA signals colocalise within the block of
SNPs in LD, represented by rs2736898, suggesting this
block is primarily responsible for driving CBG-mediated
variation for cortisol. Moreover, it demonstrates effects on
adipose tissue gene expression, suggesting that resulting
variations in CBG levels in turn influence the delivery of
cortisol to peripheral tissues.
Given previous evidence of heritability of plasma corti-
sol it is surprising that the increase in sample size and SNP
coverage from our earlier GWAMA did not identify any
new loci associated with morning plasma cortisol. Twin
studies have estimated the heritability of plasma cortisol
ranging from 14 to 45% [36–38]. However, SNP heritability
estimates of plasma cortisol are considerably lower at 6%
[15], and were confirmed in this sample at 4%. Never-
theless, despite poor prediction of plasma cortisol by com-
mon autosomal SNPs, our interrogation of the SERPINA6/
SERPINA1 locus demonstrates important insights.
To test the functional significance of SERPINA6/A1
variants we used eQTL analyses in the STARNET cohort.
A hypothesis-free approach that investigated the effect of all
580 SNPs within the SERPINA6/SERPINA1 locus on
expression of all STARNET genes in each of the seven
tissue types identified cis-eQTLs for SERPINA6 expression
in the liver, the only tissue where SERPINA6 is highly
expressed. This effect was refined to one of the LD blocks,
represented by rs2736898. Importantly, genetic variation in
Fig. 3 Scatterplot showing colocalisation of joint signal from COR-
NET GWAMA and SERPINA6 cis-eQTLs from STARNET-liver.
Includes all SNPs within 100 Kb of SERPINA6 that were present in
both datasets (n= 535). Colour bar indicates degree of LD with
rs2736898. Formal colocalisation analysis with Coloc indicates 99.2%
probability of the presence of a shared causal variant within LD block
2 mediating GWAMA and SERPINA6 cis-eQTL signal
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SERPINA6/SERPINA1 was also associated in trans-eQTL
analyses with gene expression in visceral abdominal fat and
subcutaneous fat as well as liver. These results suggest that
not only does cortisol-associated genetic variation influence
CBG expression in the liver, but it also influences cortisol
signalling in peripheral tissues, an effect that is likely to be
mediated by CBG.
CBG binds ~90% of cortisol in plasma but it is usually
thought that only the free cortisol can access tissues and
have biological effects. Patients with mutations in SER-
PINA6 [39] and animals with deletion of CBG, however,
exhibit features consistent with cortisol deficiency despite
biochemical changes in the CBG-bound rather than free
cortisol pool. Our data support the hitherto speculative
evidence that CBG is involved actively in delivery of
cortisol to peripheral tissues. We and others had proposed
that this is mediated by altered cleavage of CBG by neu-
trophil elastase in tissues [11, 12], and evidence from
immunoassays suggested that variants in SERPINA6/SER-
PINA1 might mediate their effect through altered inhibition
of neutrophil elastase by α1-antitrypsin. However, the more
detailed analyses facilitated by the expanded GWAMA
presented here do not support this interpretation since we
did not identify eQTLs for α1-antitrypsin expression.
Moreover, the reliability of immunoassays to determine
CBG cleavage has since been called into question [40].
Epidemiological analysis of cortisol has demonstrated
associations with a large number of diseases and traits
[2–9], but the direction of causality, if any, has not been
established. The improved imputation of genetic markers
Fig. 5 Bidirectional causal
estimates of the effect of the
disease or trait on morning
plasma cortisol. Estimates are
from two-sample Mendelian
randomisation analyses using
inverse variance weighting to
combine estimates from each
genetic variant
Fig. 4 Causal estimates of a 1 SD increase in morning plasma cortisol
on relevant disease and trait outcomes. Estimates are from two-sample
Mendelian randomisation analyses using inverse variance weighting to
combine estimates from each genetic variant. a Outcomes from UK
Biobank (chronic ischaemic heart disease, cases= 8755, controls=
328,444; myocardial infarction, cases= 7790, controls= 328,893;
diabetes mellitus, cases= 16,183, controls= 320,290; body mass
index, sample size= 336,107; osteoporosis, cases= 5266, controls=
331,893); (b) Equivalent outcomes from non-UK Biobank sources—
CARDIoGRAMplusC4D (coronary heart disease, cases= 60,801,
controls= 123,504; myocardial infarction, cases= 43,676, controls=
128,199), DIAGRAM (type 2 diabetes, cases= 26,488, controls=
83,964), GIANT (BMI, sample size= 339,224) and GEFOS (lumber
spine mineral density, sample size= 28,498)
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used in this analysis allowed identification of new SNPs
within the SERPINA6/A1 locus and strengthened the
instrument used in the two-sample Mendelian randomisa-
tion analyses. We tested whether genetically-elevated cor-
tisol is causally associated with cortisol-related outcomes
selected from the features of Cushing’s syndrome—a rare
condition caused by tumours secreting ACTH or cortisol—
that are highly prevalent in the general population. Con-
sistent with previous reports based on a less refined genetic
instrument [13, 14] we found evidence that cortisol causally
increases the risk of heart disease. However, we did not find
conclusive evidence that elevated cortisol causes type 2
diabetes, osteoporosis or obesity; given the relatively small
variance in cortisol accounted for by the genetic instrument,
it is possible that causal associations with additional dis-
eases and traits would be revealed by analysis of larger
sample sizes. We also tested whether common diseases and
traits underlie elevated plasma cortisol, using bidirectional
Mendelian randomisation analyses. The strongest evidence
suggested that higher BMI reduces cortisol levels, con-
sistent with prior epidemiological and experimental evi-
dence that obesity enhances clearance of cortisol from the
circulation [1].
It is arguable that morning plasma cortisol or salivary
cortisol are poor surrogates for overall cortisol exposure
given their diurnal and ultradian fluctuations and variation
with acute stress. A more robust assessment of cortisol
phenotype, perhaps from hair cortisol [41] or ambulatory
sampling of interstitial fluid over 24 h, may reveal stronger
epidemiological and genetic associations.
In summary, this large GWAMA has revealed the limited
magnitude and range of genetic effects on plasma cortisol,
but has identified a pathway from variation in the SER-
PINA6/SERPINA1 locus through variation in liver SER-
PINA6 expression to variation in CBG-mediated gene
transcription including in adipose tissue that is causally
associated with cardiovascular disease.
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